Literature DB >> 8302606

Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line.

E Graef1, W H Caselmann, J Wells, R Koshy.   

Abstract

Insertional mutagenesis of growth related genes by hepatitis B virus (HBV) DNA is presumed to play a role in hepatocarcinogenesis. Here, we report on insertional activation of the mevalonate kinase (MK) gene in the human hepatoma cell line PLC/PRF/5. Integration of HBV DNA dissociated the promoter and upstream regulatory elements of the gene from its coding sequences. This led to the over-expression of hybrid transcripts arising from an HBV promoter and the consequent over-production of functionally active mevalonate kinase. MK phosphorylates mevalonate, a major intermediate in the branched cholesterol/isoprenoid biosynthetic pathway. Isoprenylation is crucial to the functions of cellular proteins related to growth control, including the proto-oncogene ras. As the enzymes of these biosynthetic pathways are regulated at multiple points by negative feedback, both transcriptionally and at the protein level, the results discussed here support the idea that aberrant growth could result from deregulated overexpression of MK and, perhaps, other enzymes in the cholesterol pathway. These results invoke novel mechanisms by which cell transformation might occur.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302606

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Hepatitis B virus and hepatocellular carcinoma.

Authors:  P Arbuthnot; M Kew
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

2.  Double-stranded linear duck hepatitis B virus (DHBV) stably integrates at a higher frequency than wild-type DHBV in LMH chicken hepatoma cells.

Authors:  S S Gong; A D Jensen; C J Chang; C E Rogler
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

3.  Loss and acquisition of duck hepatitis B virus integrations in lineages of LMH-D2 chicken hepatoma cells.

Authors:  S S Gong; A D Jensen; C E Rogler
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 4.  Role of hepatitis B virus DNA integration in human hepatocarcinogenesis.

Authors:  Hoang Hai; Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

5.  Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach.

Authors:  Dong Ding; Xiaoyan Lou; Dasong Hua; Wei Yu; Lisha Li; Jun Wang; Feng Gao; Na Zhao; Guoping Ren; Lanjuan Li; Biaoyang Lin
Journal:  PLoS Genet       Date:  2012-12-06       Impact factor: 5.917

6.  Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake.

Authors:  Marisa Wong Medina; Feng Gao; Devesh Naidoo; Lawrence L Rudel; Ryan E Temel; Allison L McDaniel; Stephanie M Marshall; Ronald M Krauss
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

7.  Association of TIP30 expression and prognosis of hepatocellular carcinoma in patients with HBV infection.

Authors:  Xia Zhang; Lizhi Lv; Xuenong Ouyang; Shi'an Zhang; Jian Fang; Lirong Cai; Dongliang Li
Journal:  Cancer Med       Date:  2016-07-15       Impact factor: 4.452

Review 8.  HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site.

Authors:  Dake Zhang; Ke Zhang; Urlike Protzer; Changqing Zeng
Journal:  J Clin Transl Hepatol       Date:  2021-04-25

9.  [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology].

Authors:  M A Kern; K Breuhahn; M Schuchmann; P Schirmacher
Journal:  Pathologe       Date:  2007-07       Impact factor: 0.973

10.  Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis.

Authors:  S Kubo; S Nishiguchi; K Hirohashi; T Shuto; T Kuroki; S Minamitani; T Ikebe; T Yamamoto; K Wakasa; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1998-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.